Genitourinary Cancers Symposium Annual Meeting Coverage
Regular use of non-steroidal anti-inflammatory drugs for 10 years or more increased the risk of dying from renal cell carcinoma nearly 4-fold.
The protective effect was not observed with other anti-diabetic medications.
Patients who underwent upfront cytoreductive nephrectomy lived 6.4 months longer than those treated with upfront targeted therapy, a study found.
Through diet and exercise, prostate cancer patients can decrease their risk of dying from their illness.
The finding of lower bladder cancer incidence in patients receiving pelvic radiation contrasts with previous research.
Researchers estimate that 40% of pathologic response in MIBC patients receiving both neoadjuvant chemo and TURBT is due to TURBT.
A travel distance of more than 30 miles to the provider was associated with greater chances of readmission in one analysis.
Non-users of 5-alpha-reductase inhibitors had a nearly 2.6 times increased risk of pathologic progression than those who took the drugs.
Patients with higher heterogeneity score did not respond well to hormone therapy.
Second round of 6 injections was well tolerated and continued to control disease progression in bone.
A 50% or greater PSA decline at 15 days after start of treatment was associated with increased progression-free and overall survival.
Researchers observed a trend toward longer time on drug among men with castration-resistant prostate cancer.
The drug nearly doubled the delay in tumor growth compared with everolimus.
In large observational study, regular use—defined as 3 tablets per week—was associated with a 24% lower risk of dying from prostate cancer.
In a small study, high-dose testosterone given intermittently with androgen deprivation therapy lowered PSA levels without serious adverse effects.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)